ImmuPharma (LON:IMM) Trading Up 191.7% – Still a Buy?

ImmuPharma plc (LON:IMM)’s stock price shot up 191.7% during mid-day trading on Thursday . The stock traded as high as GBX 3.78 ($0.05) and last traded at GBX 3.50 ($0.04). 96,678,711 shares traded hands during mid-day trading, an increase of 468% from the average session volume of 17,022,506 shares. The stock had previously closed at GBX 1.20 ($0.01).

ImmuPharma Price Performance

The firm has a market cap of £14.58 million, a P/E ratio of -350.00 and a beta of 1.53. The firm has a fifty day simple moving average of GBX 1.36 and a 200-day simple moving average of GBX 1.63.

ImmuPharma Company Profile

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.